Longeveron (NASDAQ:LGVN) Given “Buy” Rating at HC Wainwright

Longeveron (NASDAQ:LGVN)‘s stock had its “buy” rating restated by investment analysts at HC Wainwright in a research note issued on Monday, Benzinga reports. They presently have a $10.00 price target on the stock. HC Wainwright’s target price suggests a potential upside of 392.61% from the company’s current price.

Separately, Maxim Group lowered their price target on shares of Longeveron from $15.00 to $6.00 and set a “buy” rating for the company in a report on Tuesday, August 27th.

Longeveron Stock Performance

Shares of Longeveron stock opened at $2.03 on Monday. Longeveron has a 52-week low of $0.77 and a 52-week high of $23.90. The stock has a market capitalization of $29.15 million, a price-to-earnings ratio of -0.23 and a beta of 0.36. The company has a fifty day moving average of $2.03 and a 200-day moving average of $2.10.

Longeveron (NASDAQ:LGVN) last announced its quarterly earnings data on Wednesday, August 14th. The company reported ($1.83) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($1.03) by ($0.80). Longeveron had a negative net margin of 1,513.83% and a negative return on equity of 237.57%. The business had revenue of $0.47 million during the quarter, compared to analysts’ expectations of $0.53 million. On average, equities research analysts forecast that Longeveron will post -3.89 earnings per share for the current fiscal year.

Institutional Investors Weigh In On Longeveron

A hedge fund recently bought a new stake in Longeveron stock. Renaissance Technologies LLC purchased a new stake in shares of Longeveron Inc. (NASDAQ:LGVN) in the second quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor purchased 146,700 shares of the company’s stock, valued at approximately $236,000. Renaissance Technologies LLC owned about 2.31% of Longeveron as of its most recent SEC filing. 10.01% of the stock is owned by institutional investors and hedge funds.

About Longeveron

Longeveron Inc, a clinical stage biotechnology company, develops cellular therapies for aging-related and life-threatening conditions in the United States and Japan. The company’s lead investigational product is the LOMECEL-B, an allogeneic mesenchymal stem cell formulation sourced from the bone marrow of young and healthy adult donors.